Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns

Table 1

Li percentages for Ki-67, MCM2, and MCM3 proteins in AM and AC according to clinical and histopathologic parameters.

Factors	N = 111/100%	Li%, mean ± SD
		%Ki-67	%MCM2	%MCM3
Age
≤26	56/50.4	17.4 ± 13.6	20.3 ± 10.2	34 ± 14.2
>26	55/49.5	13.4 ± 12.8	18.9 ± 10.4	30 ± 15.1
Gender
Male	60/54	17.3 ± 14.9	18.7 ± 9.4	31.6 ± 30.5
Female	51/45.9	13.1 ± 10.9	20.6 ± 11.3	32.5 ± 15.5
Size
≤5 cm	75/67.5	14.8 ± 11.9	19.4 ± 9.6	31.8 ± 14.6
>5 cm	36/32.4	16.7 ± 16	19.9 ± 11.8	32.3 ± 15.1
Location
Maxilla	3/2.7	18 ± 7.3	19.8 ± 2.4	28.5 ± 14.6
Anterior	1/0.9	12.4	18.4	20 ± 2.8
Posterior	2/1.8	20.5 ± 7.7	20.5 ± 3.5	45.4
Mandible	108/97.3	15.1 ± 13.2	19.4 ± 10.2	32.2 ± 14.9
Anterior	9/8.1	16.6 ± 18.4	22.1 ± 12.1	30.6 ± 14.2
Posterior (body and ramus)	99/89.1	15.1 ± 13.2	19.4 ± 10.2	32.2 ± 14.9
Radiography	(/100%)
Unilocular	(/69.5)	15.5 ± 14.1	19.2 ± 10.6	31.7 ± 15
Multilocular	(/30.4)	16.3 ± 12.1	21.3 ± 11.4	33.2 ± 14.3
Recurrence
Yes	6/5.4	10.6 ± 4.5	17.3 ± 11.9	23.5 ± 19
No	105/94.5	15.7 ± 13.6	19.7 ± 10.2	32.5 ± 14.4